Primary Biliary Cholangitis (PBC) is a chronic liver condition that affects the bile ducts. For many years, Ursodeoxycholic acid (UDCA) was the primary treatment. However, advancements in medical research have introduced new therapeutic agents, including Obeticholic Acid (OCA). As a pharmaceutical intermediate, OCA is a semi-synthetic bile acid analogue and a potent agonist of the Farnesoid X Receptor (FXR).

The Farnesoid X Receptor (FXR) is a nuclear receptor that plays a critical role in regulating bile acid, lipid, and glucose metabolism in the liver and intestine. By activating FXR, Obeticholic Acid helps to normalize bile acid homeostasis, reduce inflammation, and mitigate liver damage. This makes it a crucial compound for liver disease treatment. The drug development of Obeticholic Acid has shown significant promise, particularly in managing PBC, often when UDCA is insufficient or not tolerated.

Research into Obeticholic Acid also extends to other liver conditions such as nonalcoholic steatohepatitis (NASH) and portal hypertension. Its ability to modulate bile acid pathways and reduce liver fibrosis makes it a target for further clinical investigation. When sourcing Obeticholic Acid powder, it is important to ensure high purity for optimal efficacy in pharmaceutical formulations. The availability of high-quality Obeticholic Acid from reliable suppliers in China facilitates its use in advanced research and therapeutic applications.

While Obeticholic Acid offers significant benefits, it's important to note potential side effects. Some patients may experience pruritus (itching) or other liver-related adverse events. Healthcare professionals closely monitor patients for these effects to ensure safe and effective treatment. The continuous research and development of Obeticholic Acid underscore its importance in the pharmaceutical landscape, providing hope for patients with challenging liver conditions.